Dakota Johnson Named Global Brand Ambassador for Roberto Coin: Award-Winning Actress and Advocate Stars in New Jewelry Campaign
NEW YORK — Roberto Coin, the renowned Italian maison known for its sophisticated design, romance, and impeccable craftsmanship, proudly announces actress and advocate Dakota Johnson as its new Global Brand Ambassador.
Article content
Article content
This landmark partnership ushers in a dynamic new chapter for Roberto Coin, highlighting the brand's continued evolution through bold storytelling and artistry. A celebrated actress with a career spanning over two decades and a vocal advocate for mental health awareness, Johnson embodies Roberto Coin's philosophy of turning life's moments into extraordinary expressions of beauty, passion, and purpose.
Article content
Starting in June 2025 and running through May 2027, Johnson will star in a stunning new global campaign photographed by the legendary Craig McDean. Set against the breathtaking backdrop of Venice, the campaign captures the fusion of classic Italian beauty and contemporary elegance that defines Roberto Coin.
Article content
Venice serves as both the inspiration and the soul of this campaign. For Roberto Coin, the brand's founder, the connection to this iconic city is deeply personal. Born in Venice, its essence has profoundly shaped his creativity over the years. The city's rich history, majestic architecture, and vibrant artistic culture have long influenced his designs and inspired many of his collections. As such, Venice becomes the perfect backdrop and muse for this new campaign, a city of timeless beauty that perfectly mirrors the brand's elegance.
Article content
The campaign, featuring video and still photography, highlights Dakota wearing pieces from the brand's most iconic collections: Love in Verona, Venetian Princess, Navarra, Obelisco, Tiaré, and Cobra.
Article content
Released in two phases, the campaign's first half will launch in June, with the second installment debuting in May 2026. The full campaign will run through May 2027 across global platforms.
Article content
'I've always believed that jewelry tells a story—of who you are, where you've been, and what you love,' said Dakota Johnson. 'Roberto Coin's pieces are full of depth and meaning, and I'm honored to help bring that spirit to life through this collaboration. There's romance, strength, and bold femininity in every design.'
Article content
In addition to the campaign, Johnson will make global appearances and participate in creative initiatives, helping share the Roberto Coin story with a new generation.
Article content
'Dakota Johnson is a true original. I love her expressions—an artist with authenticity, depth, and a unique ability to connect,' said Roberto Coin, Founder and Creative Director. 'We are proud to welcome her to the Roberto Coin family and to collaborate on a campaign that speaks to the heart of who we are.'
Article content
Roberto Coin has been an icon in the jewelry industry for nearly 50 years. His designs include his signature collections like Appassionata, Animalier, Pois Moi and the current iconic Venetian Princess Collection. His collection is available in over 60 countries, in 200 points of sales and over 20 owned or franchise boutiques worldwide. Since 1977, Venetian jewelry designer Roberto Coin has devoted his life to a passion for innovative design, based on a deep knowledge of Italian art and craftsmanship tradition. Finding inspiration in the most unlikely of places, experimenting with light, texture, color, and pattern, Coin's style is ever evolving. His diverse collection, designed to fit every woman's uniqueness is defined by a common thread – a thoughtful balance of elegance and creativity. Included in every piece of Roberto Coin jewelry is his signature ruby. The ruby symbolizes peace, prosperity and happiness and is a special wish from the designer.
Article content
The distribution in North America is owned and operated by Watches of Switzerland Group, a leading luxury watch and jewelry retailer known for its prestigious portfolio of brands and commitment to exceptional service and client experience.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
2 hours ago
- CTV News
Maritime fans remember Ozzy Osbourne
Maritime fans remember Ozzy Osbourne Maritime fans remember Ozzy Osbourne – who passed away at the age of 76.


Globe and Mail
2 hours ago
- Globe and Mail
Advanced Ovarian Cancer Clinical Trial Pipeline Spotlight: 50+ Companies Racing to Develop Safe and Effective Therapies
DelveInsight's, 'Advanced Ovarian Cancer Pipeline Insight 2025' report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Ovarian Cancer pipeline landscape. It covers the Advanced Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Ovarian Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Advanced Ovarian Cancer Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Advanced Ovarian Cancer Pipeline Outlook Report Key Takeaways from the Advanced Ovarian Cancer Pipeline Report In July 2025, AstraZeneca announced a study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated. In July 2025, CanariaBio Inc. announced a study to compare the efficacy and safety of five administrations of oregovomab versus placebo, infused in schedule dependent sequence with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of patients with newly diagnosed advanced ovarian cancer who are planned to receive neoadjuvant treatment followed by interval debulking surgery (IDS) and adjuvant treatment. In July 2025, Incyte Corporation conducted a study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU. DelveInsight's Advanced Ovarian Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Ovarian Cancer treatment. The leading Advanced Ovarian Cancer Companies such as OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc. and others. Promising Advanced Ovarian Cancer Pipeline Therapies such as Topotecan, Paclitaxel, Carboplatin, Bevacizumab, Erlotinib, AZD0530, Olaparib and others. Discover how the Advanced Ovarian Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Advanced Ovarian Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Advanced Ovarian Cancer Clinical Trials and Studies Advanced Ovarian Cancer Emerging Drugs Profile Oregovomab: OncoQuest Oregovomab is a murine IgG against CA 125. Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in this phase II trial. In a randomized Phase II clinical trial of 97 patients, treatment with Oregovomab demonstrated a highly clinically significant outcome for both progression-free and overall survival favoring the addition of oregovomab to a standard of care chemotherapy combination of carboplatin and paclitaxel. The risk of progression and of death was reduced by more than 50% when compared to placebo, and safety data showed that oregovomab did not add incremental toxicity to the chemotherapy regimen. Stenoparib: Allarity Therapeutics Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. It is currently in Phase 2 testing for ovarian cancer with patients selected by the Stenoparib DRP. The Stenoparib DRP® is validated for ovarian cancer. It is currently being evaluated for the treatment of advanced ovarian cancer in a Phase 2 clinical trial at the Dana-Farber Cancer Institute using the Stenoparib DRP® companion diagnostic to guide patient enrollment and improve therapeutic outcome. DP-303c: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. DP-303c is under development for the treatment of HER2 low expressing solid tumors, gastric cancer including gastroesophageal junction, breast cancer, adenocarcinoma of the gastroesophageal junction, epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The drug candidate is an antibody drug conjugate that is administered by intravenous route. It acts by targeting human epidermal growth factor receptor 2 (HER2). The Advanced Ovarian Cancer pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Ovarian Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Ovarian Cancer Treatment. Advanced Ovarian Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Advanced Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Ovarian Cancer market. Get a detailed analysis of the latest innovations in the Advanced Ovarian Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Advanced Ovarian Cancer Unmet Needs Advanced Ovarian Cancer Companies OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc. and others. Advanced ovarian cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical. Advanced Ovarian Cancer Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Advanced Ovarian Cancer Therapies and key Developments @ Advanced Ovarian Cancer Market Drivers and Barriers, and Future Perspectives Scope of the Advanced Ovarian Cancer Pipeline Report Coverage- Global Advanced Ovarian Cancer Companies- OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc. and others. Advanced Ovarian Cancer Pipeline Therapies- Topotecan, Paclitaxel, Carboplatin, Bevacizumab, Erlotinib, AZD0530, Olaparib and others. Advanced Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Advanced Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Advanced Ovarian Cancer drug development? Find out in DelveInsight's exclusive Advanced Ovarian Cancer Pipeline Report—access it now! @ Advanced Ovarian Cancer Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Advanced ovarian cancer: Overview Pipeline Therapeutics Therapeutic Assessment Advanced ovarian cancer – DelveInsight's Analytical Perspective In-depth Commercial Assessment Advanced ovarian cancer Collaboration Deals Late Stage Products (Phase III) Oregovomab: OncoQuest Drug profiles in the detailed report….. Mid Stage Products (Phase II) Stenoparib - Allarity Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) DS-6000a: Daiichi Sankyo Company Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Advanced ovarian cancer Key Companies Advanced ovarian cancer Key Products Advanced ovarian cancer- Unmet Needs Advanced ovarian cancer- Market Drivers and Barriers Advanced ovarian cancer- Future Perspectives and Conclusion Advanced ovarian cancer Analyst Views Advanced ovarian cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth Curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:


Globe and Mail
2 hours ago
- Globe and Mail
United Rentals Declares Quarterly Cash Dividend
United Rentals, Inc. (NYSE: URI) announced today that its Board of Directors declared a quarterly cash dividend of $1.79 per share of URI common stock. The dividend will be payable on August 27, 2025 to stockholders of record as of August 13, 2025. About United Rentals United Rentals, Inc. is the largest equipment rental company in the world. The company has an integrated network of 1,615 rental locations in North America, 40 in Europe, 39 in Australia and 19 in New Zealand. In North America, the company operates in 49 states and every Canadian province. The company's approximately 27,500 employees serve construction and industrial customers, utilities, municipalities, homeowners and others. The company offers a fleet of equipment for rent with a total original cost of $22.09 billion. United Rentals is a member of the Standard & Poor's 500 Index, the Barron's 400 Index and the Russell 3000 Index® and is headquartered in Stamford, Conn. Additional information about United Rentals is available at